Reprinted from original article with permission from Jon Fleetwood

Semaglutide is linked to tumors, death, strokes, fertility complications including miscarriages, and heart, pancreas, kidney, and gallbladder diseases. Hundreds of U.K. children as young as six will be receiving the powerful injectable weight loss and type 2 diabetes treatment drug Ozempic (semaglutide), which is tied to cancer, death, strokes, fertility complications including miscarriages, and heart, pancreas, kidney, and gallbladder diseases.

“One arm of the trial will consist of children aged between six and 12,” while, the second “will involve kids up to 17,” the U.K.’s Daily Mail reports.

Semaglutide has been available for U.K. adults since September 2023, while the U.S. Food and Drug Administration (FDA) approved the drug for American adults in 2014.

The two-and-a-half-year U.K. trial will be sponsored by Danish pharmaceutical company Novo Nordisk, which is owned primarily by parent company Novo Nordisk Foundation and BlackRock Inc.

Both the Novo Nordisk Foundation and BlackRock are official partners of the “Great Reset”-advancing globalist consortium the World Economic Forum (WEF).

WEF partners “are the driving force behind the Forum’s programmes,” according to the organization’s website, which include promoting China, the climate change narrative, and Diversity, Equity, and Inclusion (DEI) efforts.

Semaglutide will be given to children despite the drug’s link to many diseases. Novo Nordisk received FDA approval in 2010 for a similar injectable diabetes treatment drug it also made called liraglutide, which was subsequently approved for the treatment of obesity in 2014.

The molecular formula for Semaglutide is C187-H291-N45-O59. The molecular formula for Liraglutide is similar: C172-H265-N43-O51.

Semaglutide has directly “caused” thyroid C-cell tumors (adenomas and carcinomas) in mice and rats.

The semaglutide package insert also confirms cases of MTC in patients treated with sister drug Liraglutide “have been reported in the postmarketing period.”

Despite this, the insert does not indicate that Novo Nordisk has conducted any clinical or nonclinical studies that could confirm or exclude a causal relationship between semaglutide and cancer.

The semaglutide insert simply repeats a cancer warning throughout the document.

On page 1:

Page 3:

The corpus luteum is a temporary endocrine structure in female ovaries that produces progesterone, necessary for the establishment and maintenance of pregnancy.

Pregnant rats, rabbits, and monkeys administered semaglutide suffered miscarriages, structural abnormalities, and alterations to growth.